ADAMTS5
A disintegrin and metalloproteinase with thrombospondin motifs 5
As of the edition of 20 October 2026, ADAMTS5 (A disintegrin and metalloproteinase with thrombospondin motifs 5, UniProt Q9UNA0) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UNA0
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 8
- Disease areas
- Bones, joints and muscles
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Aldumastat | Went quiet | Phase 2 | none listed |
| M6495 | Went quiet | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Lakefront Biotherapeutics | Route A |
| Merck KGaA | Route A |
The other 0 companies at ADAMTS5
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at ADAMTS5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.